GOSS
Gossamer Bio, Inc.
Price Chart
Latest Quote
$0.17
+0.01 (+4.38%)
Current Price
| Previous Close | $0.16 |
| Open | $0.16 |
| Day High | $0.18 |
| Day Low | $0.16 |
| Volume | 13,275,632 |
Stock Information
| Shares Outstanding | 488.85M |
| Total Debt | $202.93M |
| Cash Equivalents | $99.22M |
| Revenue | $55.54M |
| Net Income | $-180.40M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $83.79M |
| EPS (TTM) | $-0.79 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $143.94M |
| Sales | $55.54M |
| Income | $-180.40M |
| Book/sh | $-0.69 |
| Cash/sh | $0.20 |
| Employees | 161 |
Financial Ratios
| Quick Ratio | 1.92 |
| Current Ratio | 2.20 |
Returns & Margins
| ROA | -52.29% |
| Gross Margin | 100.00% |
| Operating Margin | -264.62% |
Ownership
| Insider Ownership | 1.70% |
| Institutional Ownership | 75.15% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.57 |
| P/S | 1.51 |
| P/B | -0.25 |
Analyst Data
| Recommendation | none |
| Target Price | $4.46 |
Technical Indicators
| SMA20 | $0.18 |
| SMA50 | $0.28 |
| SMA200 | $1.75 |
| RSI | 37.82 |
| ATR | 0.0204 |
| Shares Float | 135.07M |
| Short Float | 28.65% |
| Short Ratio | 5.49 |
| Volatility | 2.00 |
| Rel Volume | 0.84 |
Performance History
| Week | +2.40% |
| Month | -14.93% |
| Quarter | -54.16% |
| 6 Months | -95.01% |
| YTD | -94.06% |
| Year | -88.13% |
| 3 Years | -87.52% |
| 5 Years | -98.02% |
| 10 Years | -99.05% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $0.17 | 13,374,500 |
| 2026-06-22 | $0.16 | 11,641,500 |
| 2026-06-18 | $0.17 | 23,415,700 |
| 2026-06-17 | $0.18 | 23,153,100 |
| 2026-06-16 | $0.17 | 8,744,500 |
| 2026-06-15 | $0.17 | 16,232,300 |
| 2026-06-12 | $0.16 | 17,990,600 |
| 2026-06-11 | $0.18 | 22,657,800 |
| 2026-06-10 | $0.16 | 34,015,800 |
| 2026-06-09 | $0.16 | 13,174,800 |
| 2026-06-08 | $0.17 | 14,269,400 |
| 2026-06-05 | $0.17 | 13,195,800 |
| 2026-06-04 | $0.18 | 9,006,400 |
| 2026-06-03 | $0.19 | 12,271,200 |
| 2026-06-02 | $0.20 | 11,592,100 |
| 2026-06-01 | $0.20 | 19,804,300 |
| 2026-05-29 | $0.23 | 13,216,400 |
| 2026-05-28 | $0.21 | 11,699,700 |
| 2026-05-27 | $0.22 | 16,239,800 |
| 2026-05-26 | $0.22 | 13,230,300 |
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
đ° Latest News
Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk
Simply Wall St. âĸ 2026-06-18T13:08:28Z
Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ...
GuruFocus.com âĸ 2026-06-17T22:19:15ZHow The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals
Simply Wall St. âĸ 2026-06-03T10:07:50Z
Gossamer Bio (GOSS) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-27T20:17:42Z
Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS)
InvestorsHub âĸ 2026-05-18T14:14:14Z
Gossamer Bio Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-18T13:05:28Z
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-15T23:30:02Z
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-14T12:30:03Z
Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-12T21:15:01Z
How The Gossamer Bio (GOSS) Story Is Shifting After The PROSERA Miss And Cash Concerns
Simply Wall St. âĸ 2026-05-11T20:14:16Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $48,471,000 | $114,701,000 | $0 | $0 |
| Operating Revenue | $48,471,000 | $114,701,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $10,989,000 | $11,517,000 | $13,511,000 | $13,880,000 |
| Total Expenses | $211,724,000 | $174,620,000 | $173,759,000 | $218,528,000 |
| Other Income Expense | $1,814,000 | $14,022,000 | $5,456,000 | $1,447,000 |
| Other Non Operating Income Expenses | $9,289,000 | $14,022,000 | $15,456,000 | $1,512,000 |
| Net Non Operating Interest Income Expense | $-9,019,000 | $-9,738,000 | $-11,514,000 | $-12,297,000 |
| Interest Expense Non Operating | $10,989,000 | $11,517,000 | $13,511,000 | $13,880,000 |
| Operating Expense | $211,724,000 | $174,620,000 | $173,759,000 | $218,528,000 |
| General And Administrative Expense | $37,631,000 | $36,133,000 | $38,455,000 | $47,609,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-170,370,000 | $-56,528,000 | $-179,817,000 | $-229,378,000 |
| Net Interest Income | $-9,019,000 | $-9,738,000 | $-11,514,000 | $-12,297,000 |
| Interest Income | $1,970,000 | $1,779,000 | $1,997,000 | $1,583,000 |
| Normalized Income | $-162,895,000 | $-56,528,000 | $-169,817,000 | $-229,313,000 |
| Net Income From Continuing And Discontinued Operation | $-170,370,000 | $-56,528,000 | $-179,817,000 | $-229,378,000 |
| Total Operating Income As Reported | $-170,728,000 | $-59,919,000 | $-183,759,000 | $-218,593,000 |
| Net Income Common Stockholders | $-170,370,000 | $-56,528,000 | $-179,817,000 | $-229,378,000 |
| Net Income | $-170,370,000 | $-56,528,000 | $-179,817,000 | $-229,378,000 |
| Net Income Including Noncontrolling Interests | $-170,370,000 | $-56,528,000 | $-179,817,000 | $-229,378,000 |
| Net Income Continuous Operations | $-170,370,000 | $-56,528,000 | $-179,817,000 | $-229,378,000 |
| Pretax Income | $-170,458,000 | $-55,635,000 | $-179,817,000 | $-229,378,000 |
| Special Income Charges | $-7,475,000 | $0 | $-10,000,000 | $-65,000 |
| Interest Income Non Operating | $1,970,000 | $1,779,000 | $1,997,000 | $1,583,000 |
| Operating Income | $-163,253,000 | $-59,919,000 | $-173,759,000 | $-218,528,000 |
| Per Share | ||||
| Diluted EPS | $-0.75 | $-0.25 | $-1.18 | $-2.71 |
| Basic EPS | $-0.75 | $-0.25 | $-1.18 | $-2.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-150,992,000 | $-39,967,000 | $-151,921,000 | $-211,004,000 |
| Total Unusual Items | $-7,475,000 | $0 | $-10,000,000 | $-65,000 |
| Total Unusual Items Excluding Goodwill | $-7,475,000 | $0 | $-10,000,000 | $-65,000 |
| Reconciled Depreciation | $1,002,000 | $4,151,000 | $4,385,000 | $4,429,000 |
| EBITDA (Bullshit earnings) | $-158,467,000 | $-39,967,000 | $-161,921,000 | $-211,069,000 |
| EBIT | $-159,469,000 | $-44,118,000 | $-166,306,000 | $-215,498,000 |
| Diluted Average Shares | $228,519,130 | $226,228,016 | $152,621,669 | $84,574,869 |
| Basic Average Shares | $228,519,130 | $226,228,016 | $152,621,669 | $84,574,869 |
| Diluted NI Availto Com Stockholders | $-170,370,000 | $-56,528,000 | $-179,817,000 | $-229,378,000 |
| Tax Provision | $-88,000 | $893,000 | $0 | $0 |
| Other Special Charges | $7,475,000 | - | $10,000,000 | $65,000 |
| Research And Development | $174,093,000 | $138,487,000 | $135,304,000 | $170,919,000 |
| Selling General And Administration | $37,631,000 | $36,133,000 | $38,455,000 | $47,609,000 |
| Other Gand A | $37,631,000 | $36,133,000 | $38,455,000 | $47,609,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-122,760,000 | $29,492,000 | $62,769,000 | $12,077,000 |
| Total Assets | $172,249,000 | $315,292,000 | $311,916,000 | $272,450,000 |
| Total Non Current Assets | $4,605,000 | $5,404,000 | $5,397,000 | $10,570,000 |
| Other Non Current Assets | $408,000 | $283,000 | $618,000 | $680,000 |
| Current Assets | $167,644,000 | $309,888,000 | $306,519,000 | $261,880,000 |
| Other Current Assets | $18,485,000 | $10,032,000 | $10,094,000 | $6,202,000 |
| Receivables | $12,227,000 | $5,338,000 | $0 | - |
| Other Receivables | $12,227,000 | $5,338,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $136,932,000 | $294,518,000 | $296,425,000 | $255,678,000 |
| Cash And Cash Equivalents | $37,732,000 | $46,074,000 | $32,109,000 | $111,973,000 |
| Restricted Cash | - | - | - | $0 |
| Prepaid Assets | - | - | - | $6,202,000 |
| Debt | ||||
| Net Debt | $160,776,000 | $151,449,000 | $176,909,000 | $107,337,000 |
| Total Debt | $202,906,000 | $202,882,000 | $212,464,000 | $225,739,000 |
| Long Term Debt And Capital Lease Obligation | $201,968,000 | $201,921,000 | $197,549,000 | $211,143,000 |
| Long Term Debt | $198,508,000 | $197,523,000 | $197,405,000 | $207,697,000 |
| Current Debt And Capital Lease Obligation | $938,000 | $961,000 | $14,915,000 | $14,596,000 |
| Current Debt | - | - | $11,613,000 | $11,613,000 |
| Other Current Borrowings | - | - | $11,613,000 | $11,613,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $295,009,000 | $285,800,000 | $249,147,000 | $260,373,000 |
| Total Non Current Liabilities Net Minority Interest | $231,574,000 | $240,790,000 | $197,549,000 | $211,143,000 |
| Non Current Deferred Liabilities | $29,606,000 | $38,869,000 | $0 | - |
| Current Liabilities | $63,435,000 | $45,010,000 | $51,598,000 | $49,230,000 |
| Current Deferred Liabilities | $19,987,000 | $17,050,000 | $0 | - |
| Payables And Accrued Expenses | $31,299,000 | $15,004,000 | $26,389,000 | $21,100,000 |
| Interest Payable | $833,000 | $833,000 | $968,000 | $1,065,000 |
| Payables | $5,965,000 | $2,319,000 | $5,526,000 | $1,459,000 |
| Total Tax Payable | $6,000 | $0 | - | - |
| Income Tax Payable | $6,000 | $0 | - | - |
| Accounts Payable | $5,959,000 | $2,319,000 | $5,526,000 | $1,459,000 |
| Equity | ||||
| Common Stock Equity | $-122,760,000 | $29,492,000 | $62,769,000 | $12,077,000 |
| Total Equity Gross Minority Interest | $-122,760,000 | $29,492,000 | $62,769,000 | $12,077,000 |
| Stockholders Equity | $-122,760,000 | $29,492,000 | $62,769,000 | $12,077,000 |
| Gains Losses Not Affecting Retained Earnings | $-5,149,000 | $1,189,000 | $-350,000 | $-574,000 |
| Other Equity Adjustments | $-5,149,000 | $1,189,000 | $-350,000 | $-574,000 |
| Retained Earnings | $-1,438,938,000 | $-1,268,568,000 | $-1,212,040,000 | $-1,032,223,000 |
| Other | ||||
| Ordinary Shares Number | $233,677,057 | $226,604,138 | $225,409,315 | $94,423,181 |
| Share Issued | $233,677,057 | $226,604,138 | $225,409,315 | $94,423,181 |
| Tangible Book Value | $-122,760,000 | $29,492,000 | $62,769,000 | $12,077,000 |
| Invested Capital | $75,748,000 | $227,015,000 | $271,787,000 | $231,387,000 |
| Working Capital | $104,209,000 | $264,878,000 | $254,921,000 | $212,650,000 |
| Capital Lease Obligations | $4,398,000 | $5,359,000 | $3,446,000 | $6,429,000 |
| Total Capitalization | $75,748,000 | $227,015,000 | $260,174,000 | $219,774,000 |
| Additional Paid In Capital | $1,321,303,000 | $1,296,848,000 | $1,275,136,000 | $1,044,864,000 |
| Capital Stock | $24,000 | $23,000 | $23,000 | $10,000 |
| Common Stock | $24,000 | $23,000 | $23,000 | $10,000 |
| Non Current Deferred Revenue | $29,606,000 | $38,869,000 | $0 | - |
| Long Term Capital Lease Obligation | $3,460,000 | $4,398,000 | $144,000 | $3,446,000 |
| Current Deferred Revenue | $19,987,000 | $17,050,000 | $0 | - |
| Current Capital Lease Obligation | $938,000 | $961,000 | $3,302,000 | $2,983,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,211,000 | $11,995,000 | $10,294,000 | $13,534,000 |
| Current Accrued Expenses | $25,334,000 | $12,685,000 | $20,863,000 | $19,641,000 |
| Net PPE | $4,197,000 | $5,121,000 | $4,779,000 | $9,890,000 |
| Accumulated Depreciation | $-207,000 | $-183,000 | $-5,432,000 | $-6,112,000 |
| Gross PPE | $4,404,000 | $5,304,000 | $10,211,000 | $16,002,000 |
| Leases | $78,000 | $0 | $2,562,000 | $2,562,000 |
| Other Properties | $4,326,000 | $5,304,000 | $6,377,000 | $12,007,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $99,200,000 | $248,444,000 | $264,316,000 | $143,705,000 |
| Machinery Furniture Equipment | - | $0 | $1,272,000 | $1,350,000 |
| Construction In Progress | - | - | $0 | $83,000 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-171,345,000 | $-3,468,000 | $-159,158,000 | $-187,507,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-171,266,000 | $-3,468,000 | $-159,158,000 | $-187,032,000 |
| Cash Flow From Continuing Operating Activities | $-171,266,000 | $-3,468,000 | $-159,158,000 | $-187,032,000 |
| Operating Gains Losses | $-5,000 | $806,000 | $726,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-79,000 | - | - | $-475,000 |
| Investing Cash Flow | $156,358,000 | $29,023,000 | $-110,970,000 | $-1,035,000 |
| Cash Flow From Continuing Investing Activities | $156,358,000 | $29,023,000 | $-110,970,000 | $-1,035,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $201,323,000 | $119,946,000 |
| Financing Cash Flow | $6,425,000 | $-11,488,000 | $190,154,000 | $117,090,000 |
| Cash Flow From Continuing Financing Activities | $6,425,000 | $-11,488,000 | $190,154,000 | $117,090,000 |
| Net Common Stock Issuance | $0 | $0 | $201,323,000 | $119,946,000 |
| Common Stock Issuance | $0 | $0 | $201,323,000 | $119,946,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-12,581,000 | $-11,613,000 | $-5,806,000 |
| Interest Paid Supplemental Data | $10,000,000 | $10,561,000 | $12,288,000 | $12,712,000 |
| End Cash Position | $37,732,000 | $46,074,000 | $32,109,000 | $111,973,000 |
| Beginning Cash Position | $46,074,000 | $32,109,000 | $111,973,000 | $183,467,000 |
| Effect Of Exchange Rate Changes | $141,000 | $-102,000 | $110,000 | $-517,000 |
| Changes In Cash | $-8,483,000 | $14,067,000 | $-79,974,000 | $-70,977,000 |
| Proceeds From Stock Option Exercised | $6,425,000 | $1,093,000 | $444,000 | $2,950,000 |
| Net Issuance Payments Of Debt | $0 | $-12,581,000 | $-11,613,000 | $-5,806,000 |
| Net Long Term Debt Issuance | $0 | $-12,581,000 | $-11,613,000 | $-5,806,000 |
| Long Term Debt Payments | $0 | $-12,581,000 | $-11,613,000 | $-5,806,000 |
| Net Investment Purchase And Sale | $156,437,000 | $29,023,000 | $-110,970,000 | $-560,000 |
| Sale Of Investment | $383,544,000 | $523,800,000 | $330,700,000 | $237,500,000 |
| Purchase Of Investment | $-227,107,000 | $-494,777,000 | $-441,670,000 | $-238,060,000 |
| Net PPE Purchase And Sale | $-79,000 | $0 | $0 | $-410,000 |
| Purchase Of PPE | $-79,000 | $0 | $0 | $-410,000 |
| Change In Working Capital | $-13,630,000 | $39,460,000 | $-14,841,000 | $-4,459,000 |
| Change In Other Working Capital | $-6,326,000 | $55,919,000 | - | $1,618,000 |
| Change In Other Current Liabilities | $-961,000 | $-3,386,000 | $-2,982,000 | $-2,721,000 |
| Change In Other Current Assets | $-125,000 | $335,000 | $62,000 | $400,000 |
| Change In Payables And Accrued Expense | $9,124,000 | $-8,132,000 | $-8,029,000 | $-2,434,000 |
| Change In Accrued Expense | $11,871,000 | $-6,476,000 | $-12,019,000 | $-621,000 |
| Change In Interest Payable | $0 | $-135,000 | $-97,000 | $-1,000 |
| Change In Payable | $-2,747,000 | $-1,656,000 | $3,990,000 | $-1,813,000 |
| Change In Account Payable | $-2,747,000 | $-1,656,000 | $3,990,000 | $-1,813,000 |
| Change In Prepaid Assets | $-8,453,000 | $62,000 | $-3,892,000 | $296,000 |
| Change In Receivables | $-6,889,000 | $-5,338,000 | $0 | $0 |
| Other Non Cash Items | $8,460,000 | $1,086,000 | $11,321,000 | $1,228,000 |
| Stock Based Compensation | $10,555,000 | $20,619,000 | $28,518,000 | $42,553,000 |
| Amortization Of Securities | $-7,278,000 | $-13,062,000 | $-9,450,000 | $-1,405,000 |
| Depreciation Amortization Depletion | $1,002,000 | $4,151,000 | $4,385,000 | $4,429,000 |
| Depreciation And Amortization | $1,002,000 | $4,151,000 | $4,385,000 | $4,429,000 |
| Depreciation | $1,002,000 | $4,151,000 | $4,385,000 | $4,429,000 |
| Gain Loss On Investment Securities | $-5,000 | - | - | - |
| Gain Loss On Sale Of PPE | $0 | $806,000 | $726,000 | $0 |
| Net Income From Continuing Operations | $-170,370,000 | $-56,528,000 | $-179,817,000 | $-229,378,000 |
| Net Intangibles Purchase And Sale | - | $0 | $0 | $-65,000 |
| Purchase Of Intangibles | - | $0 | $0 | $-65,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-06-22